MX2022014577A - Gel intestinal de levodopa y carbidopa y metodos de uso. - Google Patents

Gel intestinal de levodopa y carbidopa y metodos de uso.

Info

Publication number
MX2022014577A
MX2022014577A MX2022014577A MX2022014577A MX2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A MX 2022014577 A MX2022014577 A MX 2022014577A
Authority
MX
Mexico
Prior art keywords
methods
levodopa
intestinal gel
carbidopa
carbidopa intestinal
Prior art date
Application number
MX2022014577A
Other languages
English (en)
Inventor
John M Lipari
Ye Huang
Alexandru Deac
Alexander RUGGLES
Thin Yu Tun
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2022014577A publication Critical patent/MX2022014577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

La presente divulgación proporciona (a) una composición farmacéutica que comprende un agente activo de levodopa y un agente activo de carbidopa y (b) métodos para tratar la enfermedad de Parkinson y afecciones asociadas que comprenden administrar la composición farmacéutica a un sujeto con enfermedad de Parkinson.
MX2022014577A 2016-07-20 2019-01-18 Gel intestinal de levodopa y carbidopa y metodos de uso. MX2022014577A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662364770P 2016-07-20 2016-07-20

Publications (1)

Publication Number Publication Date
MX2022014577A true MX2022014577A (es) 2023-01-11

Family

ID=59506369

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000849A MX2019000849A (es) 2016-07-20 2017-07-20 Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2022014577A MX2022014577A (es) 2016-07-20 2019-01-18 Gel intestinal de levodopa y carbidopa y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019000849A MX2019000849A (es) 2016-07-20 2017-07-20 Gel intestinal de levodopa y carbidopa y metodos de uso.

Country Status (9)

Country Link
US (3) US20180021280A1 (es)
EP (1) EP3487479A1 (es)
JP (2) JP2019523249A (es)
CN (1) CN109715139A (es)
AU (2) AU2017299710A1 (es)
BR (1) BR112019001082A2 (es)
CA (1) CA3031254A1 (es)
MX (2) MX2019000849A (es)
WO (1) WO2018017850A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
CN1901879A (zh) * 2003-10-31 2007-01-24 阿尔扎公司 左旋多巴和卡比多巴的给药
UA95954C2 (ru) * 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
US10130755B2 (en) * 2013-12-31 2018-11-20 Abbvie Inc. Devices and methods for delivering a beneficial agent to a user
SE538425C2 (en) * 2014-09-04 2016-06-21 Lobsor Pharmaceuticals Ab Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof
EP4356907A1 (en) * 2014-09-04 2024-04-24 LobSor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation

Also Published As

Publication number Publication date
JP2022166217A (ja) 2022-11-01
MX2019000849A (es) 2019-09-13
WO2018017850A1 (en) 2018-01-25
EP3487479A1 (en) 2019-05-29
CA3031254A1 (en) 2018-01-25
CN109715139A (zh) 2019-05-03
JP2019523249A (ja) 2019-08-22
US20180021280A1 (en) 2018-01-25
AU2023203340A1 (en) 2023-06-22
AU2017299710A1 (en) 2019-01-31
BR112019001082A2 (pt) 2019-04-30
US20230129413A1 (en) 2023-04-27
US20210059968A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12019501339A1 (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
TWD192896S (zh) 按摩器
JOP20200231A1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
PH12020500321A1 (en) Amino acid compositions for the treatment of liver disease
WO2017184871A9 (en) Carbidopa and l-dopa prodrugs and methods of use
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
ZA202002779B (en) Dantrolene prodrugs and methods of their use
MX2021002321A (es) Nuevos metodos.
MX2021004766A (es) Composiciones multifásicas.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
ZA202006986B (en) Dantrolene formulations and methods of their use
MX2021007486A (es) Hidrolizado de colageno para usarse con trastornos de la piel y trastornos intestinales.
MX2021005776A (es) Formulaciones farmaceuticas para administracion subcutanea.
AR103448A1 (es) Gel intestinal de levodopa y carbidopa y métodos de uso
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
IN2014MU01185A (es)
IN2014MU01184A (es)
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
IN2013MU02575A (es)